H
Haewon C. Kim
Researcher at University of Pennsylvania
Publications - 45
Citations - 2023
Haewon C. Kim is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Apheresis & Sickle cell anemia. The author has an hindex of 16, co-authored 45 publications receiving 1910 citations. Previous affiliations of Haewon C. Kim include Children's Hospital of Philadelphia & Pusan National University.
Papers
More filters
Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.
Zbigniew M. Szczepiorkowski,Jeffrey L. Winters,Nicholas Bandarenko,Haewon C. Kim,Michael L. Linenberger,Marisa B. Marques,Ravindra Sarode,Joseph E. Schwartz,Robert Weinstein,Beth H. Shaz +9 more
TL;DR: The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions and a new concept of a fact sheet has been introduced that succinctly summarizes the evidence for the use of therapeutic apheresis.
Journal ArticleDOI
Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease
Marie O. Russell,Herbert I. Goldberg,Andrew Hodson,Haewon C. Kim,Joanne Halus,Martin Reivich,Elias Schwartz +6 more
TL;DR: Cerebral arteriograms in 30 patients with sickle cell disease evaluated the cause of acute neurologic deficits and the effects of transfusion therapy given for a year or more after the acute episode and suggested that endothelial damage and intimal hyperplasia were the basis of stroke.
Journal ArticleDOI
Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children
Catherine S. Manno,Kathleen W. Hedberg,Haewon C. Kim,Greta R. Bunin,Susan C. Nicolson,David R. Jobes,Elias Schwartz,William I. Norwood +7 more
TL;DR: It is concluded that the transfusions of less than 48 hours old whole blood is associated with significantly less post-op blood loss than the transfusion of packed red blood cells, FFP, and platelets in children under 2 years old who underwent complex cardiac surgery.
Journal ArticleDOI
A modified transfusion program for prevention of stroke in sickle cell disease.
Alan R. Cohen,Marie Martin,Jeffrey H. Silber,Haewon C. Kim,Kwaku Ohene-Frempong,Elias Schwartz +5 more
TL;DR: Evidence is offered that a target pretransfusion HbS level of 50% affords a continuing high rate of protection against recurrent cerebral infarction in sickle cell disease after 4 years of a conventional transfusion program.
Journal ArticleDOI
Erythrocytapheresis Therapy to Reduce Iron Overload in Chronically Transfused Patients With Sickle Cell Disease
Haewon C. Kim,Noreen P. Dugan,Jeffrey H. Silber,Marie Martin,Elias Schwartz,Kwaku Ohene-Frempong,Alan R. Cohen +6 more
TL;DR: Long-term erythrocytapheresis markedly reduces or prevents iron accumulation and may prevent long-term complications of sickle cell disease without risk of iron overload and the need for chelation therapy.